{"doi":"10.1128/aac.26.2.204","title":"Comparative pharmacokinetics of YM-13115, ceftriaxone, and ceftazidime in rats, dogs, and rhesus monkeys","abstract":"<jats:p>The pharmacokinetics of YM-13115, ceftriaxone, and ceftazidime were studied in rats, dogs, and rhesus monkeys (only YM-13115 and ceftriaxone were studied in rhesus monkeys). The plasma half-lives in rats were 48 min for YM-13115, 34 min for ceftriaxone, and 14 min for ceftazidime. In dogs, they were 21.9 min for YM-13115, 50.7 min for ceftriaxone, and 49.0 min for ceftazidime. In monkeys, they were 5.30 h for YM-13115 and 3.40 h for ceftriaxone. The 24-h urinary recoveries in rats were 26.7% of the dose for YM-13115, 32.0% for ceftriaxone, and 97.1% for ceftazidime. In dogs, they were 13.3% for YM-13115, 62.5% for ceftriaxone, and 86.3% for ceftazidime. In monkeys, they were 22.5% for YM-13115 and 29.3% for ceftriaxone. The 24-h biliary recoveries in rats were 72.2% for YM-13115, 61.8% for ceftriaxone, and 0.63% for ceftazidime.</jats:p>","journal":"Antimicrobial Agents and Chemotherapy","year":1984,"id":673468,"datarank":0.5837730447165941,"base_score":3.8918202981106265,"endowment":3.8918202981106265,"self_citation_contribution":0.5837730447165941,"citation_network_contribution":0.0,"self_endowment_contribution":0.5837730447165941,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":48,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1759555,"name":"M Komiya","orcid":null,"position":1,"is_corresponding":false},{"id":1759556,"name":"C Ikeda","orcid":null,"position":2,"is_corresponding":false},{"id":1759557,"name":"A Tachibana","orcid":null,"position":3,"is_corresponding":false},{"id":423162,"name":"H Matsui","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Comparative pharmacokinetics of YM-13115, ceftriaxone, and ceftazidime in rats, dogs, and rhesus monkeys","abstract":"<jats:p>The pharmacokinetics of YM-13115, ceftriaxone, and ceftazidime were studied in rats, dogs, and rhesus monkeys (only YM-13115 and ceftriaxone were studied in rhesus monkeys). The plasma half-lives in rats were 48 min for YM-13115, 34 min for ceftriaxone, and 14 min for ceftazidime. In dogs, they were 21.9 min for YM-13115, 50.7 min for ceftriaxone, and 49.0 min for ceftazidime. In monkeys, they were 5.30 h for YM-13115 and 3.40 h for ceftriaxone. The 24-h urinary recoveries in rats were 26.7% of the dose for YM-13115, 32.0% for ceftriaxone, and 97.1% for ceftazidime. In dogs, they were 13.3% for YM-13115, 62.5% for ceftriaxone, and 86.3% for ceftazidime. In monkeys, they were 22.5% for YM-13115 and 29.3% for ceftriaxone. The 24-h biliary recoveries in rats were 72.2% for YM-13115, 61.8% for ceftriaxone, and 0.63% for ceftazidime.</jats:p>","is_dataset_classified":null,"base_score":3.8918202981106265,"endowment":3.8918202981106265,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"6091536","pmcid":"PMC284120","openalex_id":"https://openalex.org/W2161869258","authors":[],"funders":[],"total_grants":0,"fwci":1.3415,"citation_percentile":0.81836372,"influential_citations":0,"citation_trend":[{"year":2012,"count":4},{"year":2013,"count":1},{"year":2014,"count":1},{"year":2015,"count":1},{"year":2016,"count":1},{"year":2017,"count":2},{"year":2018,"count":2},{"year":2019,"count":3},{"year":2021,"count":1},{"year":2024,"count":1},{"year":2026,"count":1}],"oa_status":"green","license":"https://journals.asm.org/non-commercial-tdm-license","oa_locations":[{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/284120","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/284120","host_type":"repository"},{"url":"https://journals.asm.org/doi/pdf/10.1128/AAC.26.2.204","host_type":"publisher"},{"url":"https://doi.org/10.1128/aac.26.2.204","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/6091536","host_type":"repository"},{"url":"http://europepmc.org/pmc/articles/PMC284120","host_type":"repository"}],"fields_of_study":["Drug Transport and Resistance Mechanisms","Antibiotics Pharmacokinetics and Efficacy","Antibiotic Resistance in Bacteria","Animals","Anti-Bacterial Agents","Bile","Cefotaxime","Ceftazidime","Ceftriaxone","Cephalosporins","Dogs","Injections, Intravenous","Kinetics","Macaca mulatta","Male","Rats","Rats, Inbred Strains"],"mesh_terms":["Animals","Anti-Bacterial Agents","Bile","Cefotaxime","Ceftazidime","Ceftriaxone","Cephalosporins","Dogs","Injections, Intravenous","Kinetics","Macaca mulatta","Male","Rats, Inbred Strains","Rats"],"keywords":["Ceftriaxone","Ceftazidime","Pharmacokinetics","Medicine","Antibacterial agent","Pharmacology","Antibiotics","Anesthesia","Microbiology","Internal medicine","Biology","Bacteria","Pseudomonas aeruginosa"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-16T13:30:10.565248Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}